Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12014964 | 0.93 | HSD17B10 (0.52) | HSD17B10ALDH1A1SMN1; SMN2STAT6GAA | |
| SCHEMBL24626085 | 0.93 | HSD17B10 (0.52) | HSD17B10ALDH1A1SMN1; SMN2STAT6GAA | |
| SCHEMBL893723 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 | |
| SCHEMBL21454626 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 | |
| SCHEMBL1065178 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 | |
| SCHEMBL454245 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 | |
| SCHEMBL321552 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 | |
| SCHEMBL17512849 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 | |
| SCHEMBL336249 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 | |
| SCHEMBL3504659 | 0.89 | HSD17B10 (0.56) | HSD17B10ALDH1A1SMN1; SMN2GAASLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885ALDH1A1 3906/4885SMN1; SMN2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.